Home | About us | Editorial Board | Search | Ahead of print | Current Issue | Archives | Instructions | Online submissionContact Us   |  Subscribe   |  Advertise   |  Login  Page layout
Wide layoutNarrow layoutFull screen layout
Lung India Official publication of Indian Chest Society  
  Users Online: 170   Home Print this page  Email this page Small font size Default font size Increase font size


 
  Table of Contents    
LETTER TO EDITOR
Year : 2012  |  Volume : 29  |  Issue : 1  |  Page : 95-96  

Ethics, human rights and programmatic management of drug-resistant tuberculosis


The Maharashtra State Anti Tuberculosis Association, Hon. Secretary and Technical Adviser

Date of Web Publication28-Jan-2012

Correspondence Address:
Yatin N Dholakia
The Maharashtra State Anti Tuberculosis Association, Hon. Secretary and Technical Adviser

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0970-2113.92384

Rights and Permissions

How to cite this article:
Dholakia YN. Ethics, human rights and programmatic management of drug-resistant tuberculosis. Lung India 2012;29:95-6

How to cite this URL:
Dholakia YN. Ethics, human rights and programmatic management of drug-resistant tuberculosis. Lung India [serial online] 2012 [cited 2019 Jul 16];29:95-6. Available from: http://www.lungindia.com/text.asp?2012/29/1/95/92384

Sir,

Programmatic Management of Drug-Resistant Tuberculosis (PMDT) is being implemented in a phased manner in India since 2007. Three hundred and thirty-one million people in 150 districts across 15 states in the country are covered under DOTS Plus. So far, 4217 multi-drug resistant tuberculosis (MDR TB) patients are on treatment under this program in India. [1] MDR TB suspects from Revised National Tuberculosis Control Program (RNTCP) i.e., Category 2 failures, Category 1 failures and contacts of MDR TB patients are being subjected to sputum AFB culture and drug susceptibility test (DST) at the Intermediate Reference Laboratories (IRLs) and some accredited private labs. Under the DOTS Plus strategy, a standard treatment regimen (STR) is being followed. The regimen includes injection Kanamycin (K), Ofloxacin (OFL), Ethionamide (ETA), Cycloserine (CLY), Pyrazinamide (Z) and Ethambutol (E). PAS is available in cases where the oral medications are not tolerated. A detailed protocol for follow up and monitoring the treatment efficacy and adherence is in place. Results from DOTS Plus pilot sites have shown good treatment success rates. [2]

Pattern of DST differs among individuals depending on prior drug history and strains of M. tuberculosis in the region. A comprehensive individualized therapy is therefore necessary to control MDR TB. [3] Inadequate treatment of MDR TB can lead to poor outcomes and are a risk for extensively drug resistant tuberculosis (XDR TB). [4] Results from Peru, which was one of the first high burden countries to have piloted and implemented PMDT, have shown that individualized treatment regimen (ITR) after drug susceptibility testing is cost-effective as compared to STR and likely to be true for other high burden resource limited countries such as ours. [5] This strategy of ITR is based on WHO principles of management of MDR TB i.e., introducing three new drugs which have not been used in past and which bear no cross-resistance to the previously prescribed regimen.

The Mumbai PMDT is being implemented in three zones since July 2010 and is privileged to have the DST reports to four first line medicines Streptomycin (S), Isoniazid (H), Rifampicin (R) and Ethambutol (E) from the accredited private laboratory - Hinduja Hospital which does not test for PZA for RNTCP patients. Around 200 patients have been initiated on second-line treatment under the STR till date in Mumbai. It has been observed that at one of the peripheral public health centers in Mumbai, of the 21 MDR suspects referred for investigations: 6 (28.5%) were negative on culture, 15 (72.5%) were positive for M. Tuberculosis by culture. Two of the fifteen (13.3%) were fully sensitive to all four drugs; 11 out of the fifteen (73.3%) culture positives were resistant to all four first line drugs viz SHRE; 1/15 (6.6%) was resistant to SandH and one result is pending. In a study conducted by The Foundation for Medical Research, where patients from the above center were included, the proportion of resistance to three or more drugs including (HR+E/Z/EZ) (24%) was greater than that of resistance to HR (4%) only. [6]

In this situation following the STR using Ethambutol, with documented drug resistance, poses a danger of amplifying resistance [7] toward XDR TB; especially when the status of susceptibility to Pyrazinamide is not known. The program has an alternative drug available in the form of PAS which can be used in such instances (guidelines state that PAS can be used if other oral drugs are not tolerated or have adverse drug reactions but are silent about its use in case of resistance to any other drug in the regimen). By continuing use of a drug with documented resistance, we are placing patient's lives at risk and also may be inadvertently fueling an XDR TB epidemic. [8] Medical ethics demands that patients be provided the best care available. Also, by denying our patients the opportunity to be effectively treated [7] and cured and alleviated of the disease we are violating the basic human right of an individual.

It is time that we rise above protocols and put the health of patients and community on our priority and not wait till another epidemic to overwhelm us.

 
   References Top

1.Kumar A. Status Report on RNTCP. Indian J Tuberc 2011;58:132-5.  Back to cited text no. 1
    
2.Arora VK, Sarin R, Singla R, Khalid UK, Mathuria K, Singla N, et al. DOTS plus for multi-drug resistant tuberculosis in India: Early results after three years. Indian J Chest Dis Allied Sci 2007;49:75-80.  Back to cited text no. 2
    
3.Mitnick CD, Castro KG, Harrington M, Sacks LV, Burman W. Randomized Trials to Optimize Treatment of Multidrug-Resistant Tuberculosis: The time for action is now. PLoS Med 2007;4:e292.  Back to cited text no. 3
[PUBMED]  [FULLTEXT]  
4.Johnston JC, Sahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: A systematic review and meta-analysis. PLoS One 2009;4:e6914.   Back to cited text no. 4
    
5.Resch SC, Salomon JA, Murray M, Weinstein MC. Cost-effectiveness of treating multidrug-resistant tuberculosis. PLoS Med 2006;3:e241.  Back to cited text no. 5
[PUBMED]  [FULLTEXT]  
6.D'souza DT, Mistry NF, Vira TS, Dholakia Y, Hoffner S, Pasvol G, et al. High levels of multidrug resistant tuberculosis in new and treatment-failure patients from the Revised National Tuberculosis Control Programme in an urban metropolis (Mumbai) in Western India. BMC Public Health 2009;9:211.  Back to cited text no. 6
[PUBMED]  [FULLTEXT]  
7.Jain NK. RNTCP and tuberculosis control - High time to act. Lung India 2010;27:108-10.  Back to cited text no. 7
[PUBMED]  Medknow Journal  
8.Joshi JM. Tuberculosis chemotherapy in the 21 st century: Back to the basics. Lung India 2011;28:193-200.  Back to cited text no. 8
[PUBMED]  Medknow Journal  



This article has been cited by
1 Clinical profile and treatment outcomes of drug-resistant tuberculosis before directly observed treatment strategy plus: Lessons for the program
Dholakia YN, Shah DP
Lung India. 2013; 30(4): 316-320
[Pubmed]



 

Top
  
 
  Search
 
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
    Access Statistics
    Email Alert *
    Add to My List *
* Registration required (free)  

 
  In this article
    References

 Article Access Statistics
    Viewed1010    
    Printed39    
    Emailed0    
    PDF Downloaded285    
    Comments [Add]    
    Cited by others 1    

Recommend this journal